tazarotene foam
Selected indexed studies
- Use of tazarotene foam for the treatment of acne vulgaris. (Clin Cosmet Investig Dermatol, 2014) [PMID:24920932]
- Tazarotene foam, 0.1%, for the treatment of acne. (Expert Opin Drug Saf, 2016) [PMID:26560170]
- Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. (Clin Drug Investig, 2013) [PMID:23456673]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Use of tazarotene foam for the treatment of acne vulgaris. (2014) pubmed
- Tazarotene foam, 0.1%, for the treatment of acne. (2016) pubmed
- Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris. (2013) pubmed
- Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis. (2022) pubmed
- Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. (2013) pubmed
- Phototoxic and photoallergic potential of tazarotene foam 0.1% in 2 phase 1 patch studies. (2012) pubmed
- Pharmaceutical approval update. (2012) pubmed
- Successful treatment of median canaliform nail dystrophy with topical tazarotene foam. (2022) pubmed
- Tazarotene cream (0.1%) in combination with betamethasone valerate foam (0.12%) for plaque-type psoriasis. (2005) pubmed
- The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. (2013) pubmed